The FDA Took the Black Box Off Menopause Hormone Therapy. Here Is What Changed for Me.

I read the warning label before I ever filled the prescription.

Not skimmed it. Read it. I looked up what a boxed warning actually is, why the FDA uses one, and what the research behind that particular warning had found. Cardiovascular disease. Breast cancer. Probable dementia. All of it inside a black rectangle, which is the strongest warning the FDA puts on a drug.

Then I filled the prescription anyway.

I want to be honest about the reasoning, because it was not especially brave and it was not especially scientific. It went like this. I wanted to find out whether hormone therapy would relieve my symptoms. If it did, I would think about the long term after I knew. If it did not, I would have my answer and I would stop.

It did. The brain fog cleared. The hot flashes and night sweats stopped. My joints eased up. The low mood lifted. I could not believe how good I felt once the fog and the flashes subsided. I felt better than I had in years.

And that is when I made the decision I am still living by. I did not want to spend years suffering through symptoms in order to avoid a risk I had already read about and understood. I would rather take the risk.

That was my choice, made with the warning sitting right there in front of me. On February 12, 2026, the FDA removed a large part of that warning from the label.

What the boxed warning said, and what it did

A boxed warning is the most serious safety warning the FDA can require. It goes at the top of the prescribing information, inside a black border, and it is the first thing a prescriber sees. On menopausal hormone therapy, that box carried warnings about cardiovascular disease, breast cancer, and probable dementia.

Here is what that meant in practice. A woman who could not sleep, could not think, and could not get through a workday without her body burning from the inside out would bring it up with a doctor, and the conversation would start from fear. Not from her symptoms. Not from how many years of her life were being taken. From the black box.

I know women who were told to just get through it. I know women who were offered an antidepressant for hot flashes and nothing else. And I understand how it happened. The warning was there, the doctor had ten minutes, and the safest thing a busy clinician can do with a black box is stay away from it.

That went on for more than twenty years. It is worth naming what those years actually were, because they were not an abstraction. They were sleep, and work, and confidence, and careers, and women deciding at 45 that they were losing their minds and telling nobody. I spent about fifteen years not knowing what was happening to me, and I have written about what those years were like elsewhere on this site.

What the FDA actually changed

Let me be precise about this, because precision is the whole point of the article.

In November 2025, the FDA and the Department of Health and Human Services announced they would begin removing the boxed warnings covering cardiovascular disease, breast cancer, and probable dementia. That announcement followed an expert panel held in July 2025, a review of the research, and a public comment period.

Then on February 12, 2026, the FDA approved the first set of label changes. Six products. The agency said those six cover all four categories of menopausal hormone therapy: systemic combination therapy, systemic estrogen-alone therapy, systemic progestogen-alone therapy, and topical vaginal estrogen.

Twenty-nine drug companies have submitted proposed labeling changes at the FDA’s request. Six were approved in that first batch. So if you go and look at the label on your own prescription and the box is still there, that does not mean something went wrong. It means your product has not come through yet.

The reasoning the FDA gave centers on the study most of the original warning came from. In that study, the average participant was 63 years old, which is more than a decade past the age most women reach menopause. The formulation used is not the one commonly prescribed now. And the breast cancer finding the FDA described was a statistically non-significant increase, which is a phrase worth understanding.

What did not change

This is the part I most want women to get right, because it is the part a headline flattens.

The boxed warning about endometrial cancer is still there on systemic estrogen-alone products. When the FDA announced this in November 2025, it said plainly that it was not seeking to remove that one. If you have a uterus and you are taking systemic estrogen without a progestogen, that warning applies to you, and it is the reason a progestogen is usually prescribed alongside estrogen in the first place. Nothing about that changed.

The second thing that did not change is quieter. No new study came out on February 12. The FDA reviewed research that already existed and concluded the label had been describing it badly. That is a real and meaningful action. It is not the same thing as new evidence arriving. Your own risk profile, your family history, your blood pressure, and your history of clots or cancer are all exactly what they were the week before.

And the professional bodies did not respond with a blanket endorsement. The Menopause Society said it agreed with removing the boxed warning from low-dose vaginal estrogen, noting the warning “may have been a deterrent” to a safe and effective treatment. In the same statement it was careful to add that “systemic estrogen still comes with potential risks in certain individuals,” and that those risks belong in a real conversation covering medical history and other conditions before anyone starts.

I think that is the honest position, and I hold it too. I am an advocate for hormone therapy. I am not an advocate for anyone taking it without a conversation.

The part about timing, and who is saying it

You are going to see one line repeated everywhere in the coverage: that the benefits look most favorable for women who start within ten years of menopause, or before age 60.

I am not the source of that framing and I am not the one recommending it. It comes from the evidence base. The Menopause Society’s 2022 hormone therapy position statement puts it this way:

VMS means vasomotor symptoms, which is the clinical term for hot flashes and night sweats.

Two things follow from that quotation, and I would rather say both than only the encouraging one. The first is that if you are inside that window and you have been putting this off, the evidence is more in your favor than the old label suggested. The second is that if you are past it, this is a genuinely different conversation with different math, and you deserve a doctor who will do that math with you rather than either refusing outright or waving you through.

Why I started anyway

I want to come back to my own decision, because I do not want this article to read as though the FDA validated me. It did not, and that is not why I am writing.

By the time I started hormone therapy, I had been losing pieces of myself for years. The first thing to go was arithmetic. I had always done fairly complex calculations in my head, and I got to the point where I was counting on my fingers to add two single digit numbers. I made mistakes on work I had done for two decades. I read the same paragraph over and over without any of it going in.

Then came the hot flashes, which I can only describe as my body burning from the inside out. Then the night sweats that soaked through everything. Then joint pain in my knees and elbows that I assumed was arthritis, because that is what you assume.

So when I read that warning label, I was not weighing a comfortable life against a small risk. I was weighing a life I had already partly lost against a risk I could read about. I decided I would rather take the risk than spend the years I had left feeling the way I felt.

That is not a recommendation. Plenty of women read the same information and decide differently, and they are not wrong. It is a decision about what you are willing to trade, and only you know what your symptoms are actually taking from you.

What hormone therapy fixed for me, and what it did not

Every article on this site has a section about what did not work, and hormone therapy gets the same treatment as everything else.

What it resolved. The brain fog, completely, and that was the biggest single change in my life in a decade. The hot flashes, almost entirely. I get an occasional mild one now and it is nothing like it was. The night sweats stopped. The joint pain improved a great deal, though an anti-inflammatory diet was doing work alongside it. The low mood lifted.

What it did not touch. My sleep, which is still broken. I still wake at three in the morning and I still wake up tired no matter how long I was in bed. It did nothing for my dry skin. It did nothing for my hair, which is thinning, and nothing for my eyelashes and eyebrows, which have nearly disappeared.

I say this because “hormone therapy changed my life” and “hormone therapy fixed everything” are two different sentences, and only the first one is true. The sleep piece I have had to work at separately, and I wrote up the full routine that has actually helped if that is where you are right now.

What is different about the conversation now

Here is what I think genuinely changed, and it is not the science. It is the starting position of the appointment.

Before February, a woman asking about hormone therapy was often asking her doctor to go around a black box. Now she is asking about a medication the FDA has publicly said was being described in a way that overstated certain risks. That is a different room to walk into.

A few things that are reasonable to bring up now, phrased as questions rather than demands:

That last one matters more than people expect. Walking in with an exit plan makes it much easier for both of you to say yes to a trial.

If your doctor still says no

You are allowed to see someone else.

I say this in every article I write about menopause and I am going to keep saying it. If you have no contraindication, if your symptoms are affecting your life, and your doctor will not have the conversation with you, that is information about the doctor. It is not a verdict on your options.

Look for a clinician certified in menopause care. The Menopause Society keeps a directory of practitioners who have done that training, and it is worth using, because most physicians received very little menopause education and many will tell you so themselves.

Finding a different doctor is not being difficult. It is the same thing I did years ago when I had two months of constant cramping and the first doctor told me it was menstrual cramps and to buy a pain reliever. It was stage 2 colon cancer. I went looking for other specialists myself, and that is the only reason it was found. Nobody is going to advocate for your body harder than you will.

Your turn

I would really like to hear from you in the comments on this one.

Have you talked to your doctor about hormone therapy since the label changed? Did it go differently than the last time you asked? Are you on it and still deciding how you feel about it? Did you read the warning and decide against it, and how did you get to that? All of it is useful, including the answers that are the opposite of mine.

This is a live story rather than a finished one. Twenty-nine companies are still working through label changes, so what a woman sees on her own prescription will keep shifting through the rest of this year. What we can do in the meantime is stop making each other guess.

Sources

• FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, U.S. Food and Drug Administration, February 12, 2026.
• HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy, U.S. Food and Drug Administration, November 10, 2025.
• The Menopause Society Comments on the FDA Announcement on Hormone Therapy, The Menopause Society, November 10, 2025.
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society, Menopause, July 2022.